 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
2seventy bio
TSVT
conference date: to be acquired by Bristol-Myers
2seventy bio to be acquired by Bristol Meyers [March 10, 2025]
2seventy bio a Buy for Abecma and CAR T Platform [December 9, 2022 at Seeking Alpha]
2seventy bio Prospects [August 23, 2022 at Seeking Alpha]
| 2024 | |||
| 2seventy bio TSVT Q4 2023 |
2seventy bio TSVT Q1 2024 |
2seventy bio TSVT Q2 2024 |
2seventy bio TSVT Q3 2024 |
| March 5, 2024 | May 8, 2024 | Aug. 7, 2024 | Nov. 12, 2024 |
| 2023 | |||
| TSVT Q4 2022 Press Release |
2seventy bio TSVT Q1 2023 |
2seventy bio TSVT Q2 2023 |
2seventy bio TSVT Q3 2023 |
| March 16, 2023 | May 3, 2023 | Aug. 14, 2023 | Nov. 14, 2023 |
| 2022 | |||
| TSVT Q3 2022 Press Release |
|||
| Nov. 7, 2022 | |||
2seventy bio (TSVT) is a biotechnology company specializing in CAR-T therapies.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CLDX |
| CDTX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| IMGN |
| INCY |
| INKT |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| VSTM |
| VRTX |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers